New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson’s Disease
Voyager to Participate in Upcoming September Investor ConferencesCAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced data presentations at the International Parkinson and Movement Disorder Virtual Congress 2020 taking place on September 12-16, 2020. The presentations include new two- and three-year data related to its VY-AADC gene therapy treatment for Parkinson’s disease being developed in collaboration with Neurocrine Biosciences:Three-Year Safety and Clinical Outcomes from the PD-1101 Trial of AADC Gene Therapy for Advanced Parkinson’s Disease
Poster #879: Update on Genetics of Movement Disorders
September 13, 2020, 10:30–12:30 p.m. ET (10-minute prerecorded presentation)
AADC Gene Therapy Administered via a Posterior Approach: 24-month Results from the PD-1102 Trial in Advanced Parkinson’s Disease
Poster #889: Poster Tour
Launches on-demand on September 11, 2020, 8:00 a.m. ET (5-minute prerecorded presentation)Additionally, the company plans to participate in the following virtual investor conferences in September:Wells Fargo 2020 Virtual Healthcare Conference
Wednesday, September 9 at 1:20 p.m. ETCantor Virtual Global Healthcare Conference
Wednesday, September 16 at 2:40 p.m. ETMorgan Stanley 18th Annual Global Healthcare Conference
Friday, September 18 at 10:15 a.m. ETThe webcast sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company’s website for at least 30 days.About Voyager TherapeuticsVoyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information, please visit www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.Investor Relations:
Paul Cox
VP, Investor Relations
857-201-3463
pcox@vygr.com Media:
Sheryl Seapy
W2Opure
949-903-4750
sseapy@purecommunications.com
Bay Street News